ACRS
$10.81
Aclaris Therapts
($.06)
(.55%)
ACRS
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.36)
Revenue:  $1.78 Mil
Tuesday
Feb 1
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ACRS reports earnings?
Beat
Meet
Miss

Where is ACRS's stock price going from here?
Up
Flat
Down
Stock chart of ACRS
Analysts
Summary of analysts' recommendations for ACRS
Score
Grade
Pivots
Resistance
$11.71
$11.38
$11.09

$10.76

Support
$10.47
$10.14
$9.85
Tweet
Growth
Description
Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.